P21 vs TB-500
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
P21
P21 is a synthetic peptide derived from Cerebrolysin, specifically designed to mimic the neurotrophic effects of the parent compound. It promotes neurogenesis and has shown cognitive-enhancing properties in research.
Full details →TB-500
Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.
Full details →Side-by-Side Comparison
| Aspect | P21 | TB-500 |
|---|---|---|
| Dose Range | 1 mg–5 mg | 2 mg–2.5 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 2–4 weeks | 4–8 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Inhibits glycogen synthase kinase-3β (GSK-3β) and activates CREB signaling pathway. This promotes BDNF expression, neurogenesis in the hippocampus, and synaptic plasticity. | TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing. |
| Typical Dosage | Research protocols typically use 1-5mg administered intranasally or subcutaneously. Often used in cycles of 2-4 weeks. | Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks. |
| Administration | Can be administered intranasally for direct CNS access or subcutaneously. Best used cyclically rather than continuously. | Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites. |
| Side Effects | Limited data. Reported effects include mild headache, temporary brain fog during initial use, and fatigue. | May cause temporary fatigue, headache, or localized irritation at injection sites. |
| Best For |
Key Differences
Unique to P21:
Unique to TB-500:
Key Studies
TB-500
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
Joint diseases and related surgery, 2026
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024
- Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5.
Analytical biochemistry, 2017
Ready to Learn More?
Looking for trusted sources?